BC Week In Review | Sep 1, 2014
Clinical News

Brilacidin: Completed Phase IIb enrollment

Cellceutix completed enrollment of 215 patients with ABSSSI in a double-blind, U.S. Phase IIb trial comparing single IV doses of 0.6 and 0.8 mg/kg brilacidin and 0.6 mg/kg IV brilacidin on day 1 followed by...
BC Week In Review | Jul 14, 2014
Clinical News

Brilacidin: Phase IIb ongoing

Cellceutix said an independent DSMB recommended the continuation of a double-blind, U.S. Phase IIb trial of IV brilacidin based on an interim safety analysis after about 50% of the patients were enrolled. Cellceutix said there...
BC Week In Review | Feb 24, 2014
Clinical News

Brilacidin: Phase IIb started

Cellceutix began a double-blind, U.S. Phase IIb trial to compare single IV doses of 0.6 and 0.8 mg/kg brilacidin and 0.6 mg/kg IV brilacidin on day 1 followed by 0.3 mg/kg IV brilacidin on days...
BC Week In Review | Dec 23, 2013
Clinical News

Brilacidin: Phase IIb start

Next month, Cellceutix will begin a double-blind, U.S. Phase IIb trial to compare brilacidin vs. Cubicin daptomycin in about 200-215 patients with ABSSSI. The company plans to pursue an expedited regulatory review process for brilacidin...
BC Week In Review | Sep 23, 2013
Company News

Cellceutix infectious news

Cellceutix said it also plans to complete PolyMedix's application for an IND for a Phase II trial of brilacidin in oral mucositis and pursue Orphan Drug designation for the indication. Furthermore, Cellceutix said it is...
BC Week In Review | Sep 16, 2013
Company News

Cellceutix, PolyMedix deal

Cellceutix acquired PolyMedix's assets, including the defunct biotech's pipeline of nine compounds as well as substantial equipment assets at PolyMedix's former headquarters and laboratory. Cellceutix acquired the assets for $5 million comprised of $2.1 million...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

Despite one segment that finished the second quarter in the red, all market cap groups are still up for the year. In 2Q13, the sector was led by large caps, which closed up 4%, marking...
BC Week In Review | Apr 15, 2013
Company News

PolyMedix infectious news

PolyMedix and its PolyMedix Pharmaceuticals Inc. subsidiary filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. At Dec. 31, 2012, the company had $4.6 million in assets and $11.3...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps...
BC Week In Review | Mar 11, 2013
Financial News

PolyMedix proposes follow-on

PolyMedix Inc. (OTCBB:PYMX), Radnor, Pa.   Business: Infectious, Cardiovascular   Date announced: 3/7/13   Type: Follow-on   To be raised: About $25 million   Shares: TBD   Price prior: $0.12   Underwriters: Aegis Capital; Fordham...
Items per page:
1 - 10 of 100
BC Week In Review | Sep 1, 2014
Clinical News

Brilacidin: Completed Phase IIb enrollment

Cellceutix completed enrollment of 215 patients with ABSSSI in a double-blind, U.S. Phase IIb trial comparing single IV doses of 0.6 and 0.8 mg/kg brilacidin and 0.6 mg/kg IV brilacidin on day 1 followed by...
BC Week In Review | Jul 14, 2014
Clinical News

Brilacidin: Phase IIb ongoing

Cellceutix said an independent DSMB recommended the continuation of a double-blind, U.S. Phase IIb trial of IV brilacidin based on an interim safety analysis after about 50% of the patients were enrolled. Cellceutix said there...
BC Week In Review | Feb 24, 2014
Clinical News

Brilacidin: Phase IIb started

Cellceutix began a double-blind, U.S. Phase IIb trial to compare single IV doses of 0.6 and 0.8 mg/kg brilacidin and 0.6 mg/kg IV brilacidin on day 1 followed by 0.3 mg/kg IV brilacidin on days...
BC Week In Review | Dec 23, 2013
Clinical News

Brilacidin: Phase IIb start

Next month, Cellceutix will begin a double-blind, U.S. Phase IIb trial to compare brilacidin vs. Cubicin daptomycin in about 200-215 patients with ABSSSI. The company plans to pursue an expedited regulatory review process for brilacidin...
BC Week In Review | Sep 23, 2013
Company News

Cellceutix infectious news

Cellceutix said it also plans to complete PolyMedix's application for an IND for a Phase II trial of brilacidin in oral mucositis and pursue Orphan Drug designation for the indication. Furthermore, Cellceutix said it is...
BC Week In Review | Sep 16, 2013
Company News

Cellceutix, PolyMedix deal

Cellceutix acquired PolyMedix's assets, including the defunct biotech's pipeline of nine compounds as well as substantial equipment assets at PolyMedix's former headquarters and laboratory. Cellceutix acquired the assets for $5 million comprised of $2.1 million...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

Despite one segment that finished the second quarter in the red, all market cap groups are still up for the year. In 2Q13, the sector was led by large caps, which closed up 4%, marking...
BC Week In Review | Apr 15, 2013
Company News

PolyMedix infectious news

PolyMedix and its PolyMedix Pharmaceuticals Inc. subsidiary filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. At Dec. 31, 2012, the company had $4.6 million in assets and $11.3...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps...
BC Week In Review | Mar 11, 2013
Financial News

PolyMedix proposes follow-on

PolyMedix Inc. (OTCBB:PYMX), Radnor, Pa.   Business: Infectious, Cardiovascular   Date announced: 3/7/13   Type: Follow-on   To be raised: About $25 million   Shares: TBD   Price prior: $0.12   Underwriters: Aegis Capital; Fordham...
Items per page:
1 - 10 of 100